TABLE II.

Concerns about stopping tyrosine kinase inhibitor in the study population with chronic myeloid leukemia [cml (n = 56)]

Concern	Answered yes
	(n)	(%)	(95% ci)
Fear of
cml going out of control	45	80.4	68.2 to 88.7
Not responding to treatment if cml relapses	39	69.6	57.9 to 81.2
Having more drug side-effects if cml relapses	26	46.4	35.4 to 61.2
Being unable to afford treatment if cml relapses	25	44.6	33.0 to 58.5
Disappointing family or friends by stopping	12	21.4	13.0 to 34.4
Not getting adequate follow-up by physician	5	8.9	4.0 to 19.6